2022 LCRF and KRAS Kickers Research Grant on KRAS-Driven Lung Cancer
Matthew Gumbleton, MD, PhD
The University of Utah
KRAS inhibitors for the treatment of invasive mucinous adenocarcinoma
Invasive mucinous adenocarcinoma of the lung (IMA) is a unique, locally aggressive subtype of lung cancer that has generally not benefited from the recent advances in targeted therapies or immunotherapy strategies now commonly used to treat other types of lung cancer. This proposal will apply a combination of hypothesis testing and unbiased investigation to assess state of the art therapeutic strategies in the most physiologically relevant models of IMA currently available. We anticipate that these experiments will pave the way for clinical trials designed to determine optimal therapeutic strategies for patients with IMA.